NCT02448797 - Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation | Biotech Hunter

Enrollment

320

Participants

Timeline

Start Date

June 8, 2015

Primary Completion Date

June 30, 2022

Study Completion Date

December 31, 2023

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Icotinib

125 mg three times daily (375 mg per day) orally for two years.

DRUG

Chemotherapy

Vinorelbine 25 mg/m\^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles, cisplatin 75 mg/m\^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles. For adenocarcinoma: pemetrexed (500 mg/m\^2, day 1)/cisplatin (75 mg/m\^2, day 1) for 4 cycles.

Trial Locations (8)

100071

307 Hospital of PLA, Beijing

110001

The First Hospital of China Medical University, Shenyang

150081

First Affiliated Hospital of China Medical University, Shenyang

200433

Shanghai Pulmonary Hospital, Shanghai

310000

The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou

350014

Fujian Provincal Cancer Hospital, Fuzhou

510120

The First Affiliated Hospital Of Guangzhou Medical Collage, Guangzhou

518020

Shenzhen People's Hospital, Shenzhen